Tofranil

Nocturnal Enuresis (bedwetting), Bulimia Nervosa, Panic Disorder + 3 more
Treatment
20 Active Studies for Tofranil

What is Tofranil

ImipramineThe Generic name of this drug
Treatment SummaryImipramine is an antidepressant medication from the tricyclic antidepressant (TCA) family. It has a positive effect on mood for people with depression, but has little effect on those who are not depressed. Imipramine works by blocking serotonin and norepinephrine reuptake and by blocking certain receptors in the body. It has fewer sedative and anticholinergic effects than other TCAs, such as amitriptyline and clomipramine. Common uses of imipramine include treating depression and bedwetting in children, but it may also be used to treat chronic pain, panic
Tofranilis the brand name
image of different drug pills on a surface
Tofranil Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Tofranil
Imipramine
1959
103

Effectiveness

How Tofranil Affects PatientsImipramine is an antidepressant medication that works by blocking the reuptake of serotonin and norepinephrine in the brain. This increases the levels of these neurotransmitters, which helps to improve depressive symptoms. Imipramine has also been shown to increase neurogenesis in the hippocampus, and reduce the downregulation of this neurogenesis caused by stress. It is also thought to cause a decrease in the number of beta-adrenergic receptors in the brain.
How Tofranil works in the bodyImipramine helps to treat depression by stopping the brain from taking back two important chemicals, norepinephrine and serotonin. These chemicals are responsible for stimulating the post-synaptic neuron and when they are slowed down, they stay in the brain longer and produce changes that help relieve the symptoms of depression.

When to interrupt dosage

The recommended dosage of Tofranil is contingent upon the diagnosed affliction, including Bedwetting, Bulimia Nervosa and Depression. The measure of dosage is also influenced by the mode of delivery (e.g. Tablet, sugar coated or Tablet, sugar coated - Oral) depicted in the following table.
Condition
Dosage
Administration
Nocturnal Enuresis (bedwetting)
10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular
Bulimia Nervosa
10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular
Panic Disorder
10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular
Neuropathic Pain
10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular
Depression
10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular
Attention Deficit Hyperactivity Disorder
10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Intramuscular, Injection, solution, Injection, solution - Intramuscular

Warnings

Tofranil Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Myocardial Infarction
Do Not Combine
There are 20 known major drug interactions with Tofranil.
Common Tofranil Drug Interactions
Drug Name
Risk Level
Description
Acepromazine
Major
Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.
Aclidinium
Major
The risk or severity of adverse effects can be increased when Imipramine is combined with Aclidinium.
Alfuzosin
Major
Imipramine may increase the hypotensive activities of Alfuzosin.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Imipramine.
Amoxapine
Major
Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amoxapine.
Tofranil Toxicity & Overdose RiskImipramine can cause dry mouth, blurry vision, high body temperature, constipation, difficulty urinating, and drowsiness. It can also cause anorexia, nausea, vomiting, stomach discomfort, strange taste in the mouth, and a black tongue. Rarely, it can cause a decrease in white blood cells, platelets, and red blood cells. When taken by pregnant women, it may cause heart problems, restlessness, muscle spasms, seizures, and difficulty urinating in the baby. Taking imipramine with other drugs that increase serotonin levels can cause serotonin syndrome. The toxic dosage of imipram
image of a doctor in a lab doing drug, clinical research

Tofranil Novel Uses: Which Conditions Have a Clinical Trial Featuring Tofranil?

At present, 779 active trials are evaluating the potential of Tofranil to mitigate Attention Deficit Hyperactivity Disorder, Bulimia Nervosa and Depression.
Condition
Clinical Trials
Trial Phases
Attention Deficit Hyperactivity Disorder
63 Actively Recruiting
Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2
Nocturnal Enuresis (bedwetting)
2 Actively Recruiting
Not Applicable
Depression
304 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3
Bulimia Nervosa
0 Actively Recruiting
Panic Disorder
13 Actively Recruiting
Not Applicable
Neuropathic Pain
4 Actively Recruiting
Not Applicable, Phase 1, Phase 2

Tofranil Reviews: What are patients saying about Tofranil?

5Patient Review
6/13/2016
Tofranil for Bedwetting
I gave this to my 8 year old grandson who wet the bed every night, and it worked perfectly. His dad was 5 years old when I used this on him, and it cleared up his problem in just three days.
5Patient Review
11/18/2013
Tofranil for Problems with Bladder Control
I've been using this medication for a while now to treat my incontinence, and it's worked great! I haven't had any accidents since starting the Tofranil, and bedwetting is no longer an issue. I highly recommend this product.
5Patient Review
11/6/2015
Tofranil for Panic Disorder
I've taken this medication for over 30 years now to prevent night terrors. My doctor and I have attempted to wean me off of it several times, but each time the night terrors come back. So, as long as it keeps working, I'll keep taking it. It's been a true blessing with no negative side effects.
4.7Patient Review
2/9/2013
Tofranil for Attention Deficit Disorder with Hyperactivity
My grandson started this treatment for enuresis and ADHD when he was five years old. It worked great at first, but after six months we had to increase the dose to keep the same results. He's doing well now, but I wonder if a child can build up a tolerance to this medication over time.
4.3Patient Review
3/6/2014
Tofranil for Depression
Tofranil saved my life. After trying and failing to take Zoloft and Lexapro, I started on Tofranil at a low dose of 10mg. Every two days, I increased the dosage by 10mg until I reached 150mg--all taken at night. At first, I experienced dry mouth and blurred vision; however, after just a few weeks, I felt so much better. My depression had lifted, my panic was manageable, and my anxiety was back to normal.
3.7Patient Review
5/22/2012
Tofranil for Anxious
1Patient Review
10/10/2016
Tofranil for Bedwetting
I would not recommend this medication to anyone. My son began taking it for bedwetting and very quickly started exhibiting signs of severe emotional distress, including self-harm and outbursts of violence. I contacted his doctor right away and had him taken off the medication.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about tofranil

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What type of drug is Tofranil?

"In chemistry, generally speaking, organic compounds are any chemical compounds that contain either carbon-hydrogen or carbon-carbon bonds. The reason for this is that carbon has the ability to catenate, or form chains with other carbon atoms. This results in there being millions of known organic compounds."

Answered by AI

What is Tofranil used to treat?

"This medication is typically used to treat depression, but it can also be used in conjunction with other therapies to treat nighttime bed-wetting in children. This medication may improve your mood, sleep, appetite, and energy level, and restore your interest in daily living."

Answered by AI

What does Tofranil do to the brain?

"It is believed that Tofranil elevates mood by increasing the levels of neurotransmitters in the brain."

Answered by AI

Does Tofranil help with anxiety?

"When other stimulants are not effective, Tofranil, a tricyclic antidepressant, may be prescribed. Tofranil can be effective in treating symptoms of ADHD in adults, as well as depression and anxiety that often accompany ADHD."

Answered by AI

Clinical Trials for Tofranil

Image of St. Jude Children's Research Hospital in Memphis, United States.

Methylphenidate for Sickle Cell Disease

8 - 17
All Sexes
Memphis, TN
The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.
Phase 1
Recruiting
St. Jude Children's Research HospitalAndrew Heitzer, PhD
Image of University of California San Diego in La Jolla, United States.

AI Chatbot for Postpartum Loneliness

18+
Female
La Jolla, CA
The goal of this clinical trial is to learn whether a postpartum chatbot powered by generative artificial intelligence (genAI) can help new mothers get better pelvic floor health information and feel less lonely after childbirth. The main questions this study aims to answer are: * Does using the chatbot improve postpartum pelvic floor health knowledge? * Does using the chatbot help reduce feelings of loneliness during the postpartum period? * Does using the chatbot impact pelvic floor symptoms? Researchers will compare standard postpartum care to standard care plus the chatbot. Participants will: Be assigned by chance (like flipping a coin) to standard postpartum care with or without access to the chatbot. If in the chatbot group, participants will receive education and support via the chatbot over a 4-week period. Both groups will complete questionnaires to measure their pelvic floor knowledge, pelvic floor symptoms, feelings of loneliness, depression, infant bonding, perceived social support, adverse childhood experiences, and peri-traumatic distress. The chatbot was created by urogynecology experts in collaboration with UC San Diego computer science and biomedical informatics researchers. The chatbot is designed to give new mothers personalized, evidence-based information and support in real time.
Waitlist Available
Has No Placebo
University of California San Diego
Image of Mayo Clinic in Florida in Jacksonville, United States.

Virtual Reality for Cancer

18 - 90
All Sexes
Jacksonville, FL
This clinical trial tests the safety, tolerability, and effectiveness of a virtual reality intervention to improve psychological symptom burden for cancer patients undergoing treatment. Virtual reality (VR) is a technology that allows users to experience and interact with three-dimensional, computer-generated environments that simulate the real world or imagined settings. The VR intervention consists of a preloaded with immersive environments designed to engage the senses through simulated sights and sounds. This may include a walk through of a serene forest, exploring vibrant coral reefs, swimming with dolphins, or standing at the base of a majestic waterfall. These environments are created to provide a relaxing and engaging experience. Completing the VR intervention may be a safe and effective way to improve quality of life, reduce anxiety, enhance focus, and promote healthy living for cancer patients undergoing treatment.
Recruiting
Has No Placebo
Mayo Clinic in FloridaJuan C. Cardenas Rosales, MD
Have you considered Tofranil clinical trials? We made a collection of clinical trials featuring Tofranil, we think they might fit your search criteria.Go to Trials
Image of Virtual/ No Physical Facility in Palm City, United States.

Akashic Records Sessions for Mental Health

18+
All Sexes
Palm City, FL
The goal of this clinical study is to learn the impact of two Akashic Records sessions on mental health symptoms in adults. We want to see how sessions are linked to stress, anxiety, and depression, and to resilience (ability to bounce back) and feelings of connectedness (to self, community, and humanity). Main questions this study will answer are: After two sessions, what is the impact on stress, anxiety, and depression? After two sessions, what is the impact on resilience and connectedness? How do participants describe their experience of the sessions? After two sessions, what are participants' views of their problems (insight), emotional experiences (impact) and observable behaviors in their daily life? What participants will do: Complete online surveys about their mood at four points: before the first session, before the second session, after the second session, and again 2 months later. Surveys include: DASS-21 (Depression, Anxiety, and Stress Scale) CD-RISC-10 (Connor-Davidson Resilience Scale) WATTS (Connectedness Scale) A short demographic form and satisfaction survey Attend two individual Akashic Records sessions (50-90 minutes each) over private video platform with a licensed clinical social worker (principal investigator) The first 50 participants will also join a one-hour interview with open ended questions with a licensed clinical social worker (co-investigator) about one week after the second session to share their experience in their own words. Who can take part: Adults ages 18 and older who can read and consent in English and who have experienced stress, anxiety, or low mood in the past year. How the research will happen: Sessions are held by secure video call. Participants will also complete private online surveys before, during, and after the sessions. Some participants may be invited to share their experiences in a one-on-one interview. All information is kept private and names are removed before analysis. Risks and benefits: Talking about personal topics may bring up strong emotions. Licensed clinicians conduct sessions, offer support, and provide referrals if needed. Possible benefits include new insights, greater peace or meaning, and improved coping; benefits are not guaranteed. Why this matters: Many people seek spiritual or transpersonal support for emotional concerns. This pilot study will provide early evidence on whether Akashic Records sessions may be a helpful, low-risk option and will guide future research.
Waitlist Available
Has No Placebo
Virtual/ No Physical FacilityCandice S Rasa, LCSW
Image of University of California, Los Angeles in Los Angeles, United States.

Virtual Reality Reward Training for Depression

18+
All Sexes
Los Angeles, CA
The purpose of this study is to compare the effects of enhanced Virtual Reality-Reward Training (eVR-RT) with an active control condition, Virtual Reality-Memory Training (VR-MT), on positive affect and other clinical symptoms. Enhanced VR-Reward Training is a novel intervention aimed at enhancing savoring of positive experiences among individuals with depression and low positive affect through guided imaginal recounting following immersion in positive VR experiences. The current study tests an enhanced version of this training using improved virtual reality technology. Target enrollment is 80 participants with low positive affect, depression, and impaired functioning, who are at least 18 years old, who will be randomly assigned to 7 weeks of either enhanced Virtual Reality-Reward Training (VR-RT) or Virtual Reality-Memory Training (VR-MT). Participants will complete in-person VR sessions, laboratory assessments, self-report questionnaires as part of the study. A subset of 8 participants randomly assigned to VR-RT will complete fMRI scans and EMA surveys. The total length of participation is around 3 months.
Phase 2
Recruiting
University of California, Los Angeles
Have you considered Tofranil clinical trials? We made a collection of clinical trials featuring Tofranil, we think they might fit your search criteria.Go to Trials
Image of Center for Technology and Behavioral Health (CTBH), Geisel School of Medicine at Dartmouth College in Lebanon, United States.

Advertising Claims for Anxiety and Depression

18+
All Sexes
Lebanon, NH
In the U.S., legal cannabis is frequently advertised as an effective treatment for mental health problems such as anxiety and depression-particularly online. States that have legalized cannabis have not implemented regulations to address this type of advertising. This project aims to investigate the influence of psychotherapeutic advertising claims (PAC) and mental health warning labels (WL) on online cannabis purchasing behaviors among light-to-moderate cannabis users with symptoms of depression and/or anxiety. The specific aims are to determine whether PAC increases cannabis purchasing intentions and whether a mental health WL can mitigate this effect. A realistic online cannabis shopping experience will be simulated using the digital Platform for Online Evaluation of Marijuana Marketing and Sales (POEMMS). The study will employ a between-subjects experimental design by randomizing 2,000 participants to one of four online stores that vary in PAC and WL content: (1) a control claims (CC)-only store, (2) a PAC store, (3) a WL store, and (4) a PAC + WL store. Participants will browse and select items as if making real purchases. Analyses will examine three primary outcomes to determine the influence of PAC and WL on purchasing behaviors: (1) total milligrams of THC purchased, (2) average potency (%THC) of products, and (3) overall number of products purchased. The long-term objective is to inform evidence-based cannabis policy and regulatory strategies by understanding the impact of cannabis marketing on vulnerable populations. This research is relevant to public health by addressing the potential risks associated with misleading cannabis marketing, which may lead to increased use and exacerbation of mental health symptoms among individuals with depression and anxiety. The project leverages a multidisciplinary team with expertise in addiction, mental health, epidemiology, and digital health technology. The findings have the potential to inform the development of targeted interventions and policies to reduce harms associated with cannabis advertising-ultimately contributing to better health outcomes and more effective regulation.
Waitlist Available
Has No Placebo
Center for Technology and Behavioral Health (CTBH), Geisel School of Medicine at Dartmouth CollegeJames Sargent, MD
Image of UCSF Nancy Friend Pritzker Psychiatry Building in San Francisco, United States.

Trigeminal Nerve Stimulation for ADHD in Children with Autism

7 - 14
All Sexes
San Francisco, CA
The goal of this clinical trial is to learn if external trigeminal nerve stimulation (eTNS) works to treat ADHD symptoms in children on the autism spectrum (ASD). It will also learn about the efficacy and tolerability of the eTNS device. The main questions it aims to answer are: * Does eTNS reduce ADHD symptoms? * Does eTNS improve core and associated features of ASD? Participation spans 8-12 weeks and includes: * 4-5 in-person visits * 4 brief virtual check-ins * Nightly use of the eTNS device with a small sticky patch applied to child's forehead * Randomized assignment (those who start with the sham device may try the active device later)
Recruiting
Device
UCSF Nancy Friend Pritzker Psychiatry Building
Image of The University of Texas at Austin in Austin, United States.

Transcranial Photobiomodulation for ADHD

18 - 44
All Sexes
Austin, TX
The investigators have previously shown that non-invasive methods of brain stimulation such as the administration of transcranial infrared light to the prefrontal cortex (PFC) can result in improvements to cognition and emotion as well as brain oxygenation. This method is called transcranial photobiomodulation (tPBM). The investigators hypothesize that tPBM can improve cognition and brain oxygenation in adults with attention deficit hyperactivity disorder (ADHD). The investigators will investigate the effects of repeated tPBM sessions on cognitive functioning in adults with ADHD. Specifically, the investigators hypothesize that participants that receive tPBM will show improvements in response control, sustained attention, and working memory, as well as improvements in prefrontal hemodynamics and a reduction in ADHD symptoms.
Waitlist Available
Online Trial
The University of Texas at Austin
Image of Syracuse VA Medical Center, Syracuse, NY in Syracuse, United States.

Self-Help Intervention for Depression and PTSD

18+
All Sexes
Syracuse, NY
It is important to provide support and resources for the many post-9/11 Veterans with mental health symptoms and poor psychosocial functioning who do not engage in psychotherapy. One of the biggest reasons post-9/11 Veterans do not seek treatment is a preference to handle problems on their own. This study examines a self-help intervention that teaches Veterans healthy coping strategies they can use on their own and how to seek out recovery support services such as mental health treatment or whole-person care if they decide to do so in the future. This study will compare the impact of self-help and standard resources at improving mental health and resource utilization. Two hundred Veterans will complete 6 brief assessments across 40 weeks.
Waitlist Available
Has No Placebo
Syracuse VA Medical Center, Syracuse, NY (+1 Sites)Robyn L. Shepardson, PhD
Have you considered Tofranil clinical trials? We made a collection of clinical trials featuring Tofranil, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security